Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAY 1128688

Next Previous
Drug Profile

BAY 1128688

Alternative Names: BAY-1128688

Latest Information Update: 25 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Class
  • Mechanism of Action AKR1C3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Endometriosis

Most Recent Events

  • 30 Nov 2020 Discontinued - Phase-I for Endometriosis (In volunteers) in Germany (PO) (Bayer pipeline, November 2020)
  • 30 Nov 2020 Discontinued - Phase-II for Endometriosis in United Kingdom, Poland, Netherlands, Italy, Hungary, Germany, France, Finland, Denmark, Czech Republic, Belgium, Austria, Spain (PO) (Bayer pipeline, November 2020)
  • 20 Jul 2018 Bayer terminates the phase II AKRENDO1 trial in Endometriosis in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Poland, Spain and United Kingdom due to hepatotoxicity (NCT03373422) (EudraCT2017-000244-18)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top